193. Prader-Willi syndrome Clinical trials / Disease details
Clinical trials : 111 / Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01444898 (ClinicalTrials.gov) | March 2012 | 27/9/2011 | Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome | Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: Exenatide | Children's Hospital Los Angeles | NULL | Completed | 13 Years | 20 Years | All | 10 | N/A | United States |
| 2 | EUCTR2010-023179-25-GB (EUCTR) | 13/09/2011 | 27/07/2011 | Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi Syndrome | Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi Syndrome | Ghrelin levels in patients with Prader Willi Syndrome and healthy controls and response of ghrelin levels to a single exenatide injection compared with placebo (0.9% sodium chloride) injection. MedDRA version: 14.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Byetta Product Name: Byetta Product Code: EU/1/06/362/003: 5µg (1 pen) INN or Proposed INN: exenatide | Aintree University Hospital NHS Foundation Trust | UNIVERSITY OF LIVERPOOL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | United Kingdom | ||||
| 3 | NCT00551343 (ClinicalTrials.gov) | October 2007 | 29/10/2007 | Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome | Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome. | Prader-Willi Syndrome | Drug: Exenatide | Garvan Institute of Medical Research | NULL | Completed | 18 Years | 45 Years | All | 20 | N/A | Australia |